RECENT NEWS
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already...
Read More
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling...
Read MoreImmix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines...
Read MoreImmix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
– Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s...
Read MoreIMMIX BIOPHARMA
Prioritizing Patient wellbeing
Prioritizing patient well-being with innovative treatments that simplify and enhance the recovery process.
Voices of Hope: Real Stories from AL Amyloidosis Warriors
Discover the transformative journeys of individuals who have bravely navigated their treatment with our groundbreaking therapy. Hear firsthand how their lives have been changed and their futures reimagined.
Learn MoreSupport groundbreaking advancements in healthcare
Seize the opportunity to support groundbreaking advancements in healthcare that promise both significant patient impact and strong investment potential.
AL Amyloidoisis And Immune-mediated Disease CAR-T Clinical Trailblazer
Immix Biopharma (NASDAQ : IMMX) is a leader in pioneering AL Amyloidosis and immune-mediated disease CAR-T therapies. Our strategic approach to innovation and market potential positions us as a prime candidate for investors seeking to impact the healthcare landscape and achieve substantial returns.
Learn MoreCutting-edge research and transformative technologies
Driving the next wave of medical breakthroughs with cutting-edge research and transformative technologies in AL Amyloidosis and select immune-mediated disease therapy.
IMMIXBIO N-GENIUS sterically-optimized Cell Therapy Platform
Our N-GENIUS platform, with EXPAND technology, has produced our pioneering lead candidate, CAR-T NXC-201, which has demonstrated an enhanced tolerability profile with the potential to reduce hospitalizations.
Learn MoreCAR-T Clinical Trailblazer in AL Amyloidosis and immune-mediated diseases
Leading the charge AL Amyloidosis and select immune-mediated disease care as trailblazers of innovative CAR-T therapies, reshaping treatment landscapes and patient outcomes.
Hear from the Team
Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and immune-mediated diseases. Hear their insights and learn about the passion that drives our mission forward.
Learn MoreCAR-T THERAPY
Despite impressive research and development progress in CAR-T cell therapies, today 95% of U.S. medical centers are unable to dose CAR-T cell therapies due to neurotoxicity, and only a narrow band of patients in specific indications are able to benefit from CAR-Ts.
“Today, CAR-T cell therapies generate greater than $3 billion of annualized sales, even though due to neurotoxicity and side effects, they are dosed in only 5% of U.S. hospitals. NXC-201 has been dosed in a large number of patients across released/refractory AL amyloidosis and relapsed/refractory multiple myeloma. We believe NXC-201 could offer hope to those on waiting lists for CAR-T cell therapies, and potentially become the first out-patient CAR-T expanding into to the remaining 95% of U.S. hospitals.”
IMPACTING AL AMYLOIDOSIS AND select immune-mediated diseases
At ImmixBio, we are aiming to become the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity. By overcoming neurotoxicity, we aim to expand into select immune-mediated diseases that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies).
INDUSTRY LEADING PARTNERS
Immix Biopharma collaborates with top-tier industry leaders to accelerate our research and development efforts. Together, we are committed to advancing groundbreaking therapies that promise to transform patient outcomes in AL Amyloidosis and select immune-mediated diseases.
BE A PART OF THE FUTURE OF HEALTHCARE
Subscribe to our newsletter for exclusive updates on pioneering medical breakthroughs, the newest research developments, and innovative treatments. Stay connected and play a role in shaping the future of healthcare. Register now!